Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Astria Therapeutics (ATXS), a biopharmaceutical company developing therapies for allergic and immunologic diseases, has granted 58,650 stock options to two new employees under its 2022 Inducement Stock Incentive Plan. The options were granted on January 2, 2025, with an exercise price of $8.97, matching the closing price of Astria's common stock on the grant date.
The options will vest over a four-year period, with 25% vesting after the first year of employment and the remaining shares vesting monthly over the following 36 months. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4), which allows for inducement grants to new employees.
Astria Therapeutics (ATXS), un'azienda biofarmaceutica che sviluppa terapie per malattie allergiche e immunologiche, ha concesso 58.650 opzioni azionarie a due nuovi dipendenti nell'ambito del suo Piano di Incentivazione Stock Inducement 2022. Le opzioni sono state concesse il 2 gennaio 2025, con un prezzo di esercizio di $8,97, corrispondente al prezzo di chiusura delle azioni ordinarie di Astria alla data di concessione.
Le opzioni si acquisiranno nel corso di un periodo di quattro anni, con il 25% che si acquisisce dopo il primo anno di lavoro e le azioni rimanenti che si acquisiscono mensilmente nei successivi 36 mesi. Le concessioni sono state effettuate in conformità con Nasdaq Listing Rule 5635(c)(4), che consente concessioni di incentivazione a nuovi dipendenti.
Astria Therapeutics (ATXS), una compañía biofarmacéutica que desarrolla terapias para enfermedades alérgicas e inmunológicas, ha otorgado 58,650 opciones sobre acciones a dos nuevos empleados bajo su Plan de Incentivo de Acciones de Inducción 2022. Las opciones fueron otorgadas el 2 de enero de 2025, con un precio de ejercicio de $8.97, igual al precio de cierre de las acciones comunes de Astria en la fecha de concesión.
Las opciones adquirirán derechos a lo largo de un período de cuatro años, con el 25% adquiriéndose después del primer año de empleo y las acciones restantes adquiriéndose mensualmente durante los siguientes 36 meses. Las concesiones se hicieron de acuerdo con la Regla de Listado 5635(c)(4) de Nasdaq, que permite concesiones de inducción a nuevos empleados.
Astria Therapeutics (ATXS)는 알레르기 및 면역 질환 치료제를 개발하는 생명공학 회사로, 2022 유도 주식 인센티브 계획에 따라 두 명의 신규 직원에게 58,650개의 주식 옵션을 부여했습니다. 이 옵션은 2025년 1월 2일에 부여되었으며, 행사 가격은 $8.97로, 부여일의 Astria 보통 주식 종가와 일치합니다.
옵션은 4년 기간에 걸쳐 취득되며, 첫 해가 끝난 후 25%가 취득되고 나머지 주식은 다음 36개월에 걸쳐 매월 취득됩니다. 이번 부여는 Nasdaq 상장규정 5635(c)(4)에 따라 신규 직원에게 유도 부여가 허용되는 규정에 따라 이루어졌습니다.
Astria Therapeutics (ATXS), une entreprise biopharmaceutique développant des thérapies pour les maladies allergiques et immunologiques, a accordé 58 650 options d'achat d'actions à deux nouveaux employés dans le cadre de son Plan d'Incitation d'Actions de 2022. Les options ont été accordées le 2 janvier 2025, avec un prix d'exercice de $8,97, correspondant au prix de clôture de l'action ordinaire d'Astria à la date d'octroi.
Les options s'acquerront sur une période de quatre ans, avec 25 % qui s'acquerront après la première année d'emploi et les actions restantes s'acquérant mensuellement pendant les 36 mois suivants. Les concessions ont été faites conformément à la règle de cotation 5635(c)(4) du Nasdaq, qui permet les concessions d'incitation aux nouveaux employés.
Astria Therapeutics (ATXS), ein biopharmazeutisches Unternehmen, das Therapien für allergische und immunologische Krankheiten entwickelt, hat 58.650 Aktienoptionen an zwei neue Mitarbeiter im Rahmen seines Incentive-Programms für Aktienvergaben von 2022 gewährt. Die Optionen wurden am 2. Januar 2025 gewährt, zu einem Ausübungspreis von $8,97, der dem Schlusskurs der Stammaktien von Astria am Tag der Gewährung entspricht.
Die Optionen werden über einen Vierjahreszeitraum vesten, wobei 25% nach dem ersten Beschäftigungsjahr und die restlichen Aktien monatlich über die folgenden 36 Monate vesten. Die Gewährungen erfolgten gemäß Nasdaq Listing Rule 5635(c)(4), die Induktionsvergaben für neue Mitarbeiter zulässt.
- None.
- None.
The options were granted as an inducement material to two employees entering into employment with Astria in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of
About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Our lead program, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com, or follow us on X and Instagram @AstriaTx and on Facebook and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250103764337/en/
Astria Contact:
Investor Relations and Media:
Elizabeth Higgins
investors@astriatx.com
Source: Astria Therapeutics, Inc.
FAQ
What is the exercise price of ATXS stock options granted on January 2, 2025?
How many stock options did Astria Therapeutics (ATXS) grant in January 2025?
What is the vesting schedule for ATXS inducement stock options granted in January 2025?
Under which plan did Astria Therapeutics issue its January 2025 stock options?
